319 related articles for article (PubMed ID: 17293229)
1. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
[TBL] [Abstract][Full Text] [Related]
4. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
5. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
[TBL] [Abstract][Full Text] [Related]
8. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
[TBL] [Abstract][Full Text] [Related]
9. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320
[TBL] [Abstract][Full Text] [Related]
10. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
[TBL] [Abstract][Full Text] [Related]
12. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
[TBL] [Abstract][Full Text] [Related]
13. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
[TBL] [Abstract][Full Text] [Related]
14. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
[TBL] [Abstract][Full Text] [Related]
15. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Spencer S; Wheeler R; Peters G; Meredith R; Beenken S; Nabel L; Wooten A; Soong SJ; Salter M
Head Neck; 2003 Feb; 25(2):118-22. PubMed ID: 12509794
[TBL] [Abstract][Full Text] [Related]
17. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
[TBL] [Abstract][Full Text] [Related]
19. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
[TBL] [Abstract][Full Text] [Related]
20. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
